These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30997872)

  • 41. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 42. [A Case in Which Toxic Epidermal Necrosis Developed during Treatment with the Immune Checkpoint Inhibitor Pembrolizumab for Recurrent Patients Following Lung Cancer Surgery].
    Tsujita T; Takahashi S; Oinuma T; Hata N
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1641-1644. PubMed ID: 30449854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sick sinus syndrome associated with anti-programmed cell death-1.
    Hsu CY; Su YW; Chen SC
    J Immunother Cancer; 2018 Jul; 6(1):72. PubMed ID: 30012209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab.
    Cho WH; Chiang WY
    Front Ophthalmol (Lausanne); 2022; 2():1021574. PubMed ID: 38983552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge.
    Lee DH; Armanious M; Huang J; Jeong D; Druta M; Fradley MG
    J Oncol Pharm Pract; 2020 Sep; 26(6):1544-1548. PubMed ID: 32089073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New drugs and new toxicities: pembrolizumab-induced myocarditis.
    Inayat F; Masab M; Gupta S; Ullah W
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
    Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.
    Lederhandler MH; Ho A; Brinster N; Ho RS; Liebman TN; Lo Sicco K
    J Drugs Dermatol; 2018 Jul; 17(7):807-809. PubMed ID: 30005106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab.
    Men M; Tsui E
    Am J Ophthalmol Case Rep; 2022 Sep; 27():101631. PubMed ID: 35774195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pembrolizumab-induced optic neuropathy - a case report.
    Daetwyler E; Zippelius A; Meyer P; Läubli H
    Front Immunol; 2023; 14():1171981. PubMed ID: 37228591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
    Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
    Murakami S; Nagano T; Nakata K; Onishi A; Umezawa K; Katsurada N; Yamamoto M; Tachihara M; Kobayashi K; Nishimura Y
    Intern Med; 2019 Oct; 58(19):2839-2843. PubMed ID: 31243239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab.
    Chaudhari S; Leon A; Levin E; Neuhaus I; Liao W
    J Drugs Dermatol; 2017 May; 16(5):513-515. PubMed ID: 28628690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S; Nguyen R; Opie JM; Andrews MC
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy.
    Papaxoinis G; Anastasopoulou A; Laskari K; Diamantopoulos P; Benopoulou O; Gogas H
    Medicine (Baltimore); 2020 Mar; 99(10):e19439. PubMed ID: 32150095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
    Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Posterior Uveitis Associated with Cemiplimab.
    Dow ER; Hou K; Ransome S; Abbassi S; Tsui E
    Ocul Immunol Inflamm; 2022 Jul; 30(5):1211-1213. PubMed ID: 33793370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.